Search results
Results from the WOW.Com Content Network
Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), [6] also known as B-lymphocyte stimulator (BLyS). [7] It is approved in the United States [ 8 ] and Canada, [ 9 ] and the European Union [ 5 ] to treat systemic lupus erythematosus and lupus nephritis.
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).
This is a list of the States of India ranked in order of percentage of children between 12–23 months of age who received all recommended vaccines, including all required doses of the BCG vaccine, Hepatitis B vaccine, polio vaccine, DPT vaccine, and the MMR vaccine. This information was compiled from National Family Health Survey - 4 and 5 ...
Sales of Human Genome Sciences' (NAS: HGSI) new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. The stock traded down more than 20% today after net sales ...
Slow and steady might win the race, but it isn't a way to keep biotech investors' interest. As we approach a year after GlaxoSmithKline (NYS: GSK) and Human Genome Sciences' (NAS: HGSI) Benlysta ...
It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. [13] [8] [10] The combination of two antibodies is intended to prevent mutational escape. [14] It is also available as a co-formulated product. [13]
Shares of Ariad Pharmaceuticals (NAS: ARIA) hit a 52-week high today. Let's look at how the company got there to find out whether clear skies remain on the horizon. How it got here A drug approval ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us